FSH vs estradiol vs AMH in perimenopause: which test is most useful?
FSH vs estradiol vs AMH: how each hormone test performs in perimenopause, when to use it, and which to request first for the clearest answer.
Your doctor orders an FSH. It comes back at 14 mIU/mL. “You’re not in menopause yet,” you are told. Three months later, you ask for an estradiol test. Normal range. A year after that, an AMH. Undetectable. Nothing about your cycle, your sleep, or your energy has improved — and three different hormone tests told three different stories.
FSH, estradiol, and AMH measure different pieces of the same system. Each is useful for a different question, and each can mislead when used as a standalone diagnosis. Knowing when testing is appropriate — and when symptoms and cycle history are more useful — is the difference between a clearer conversation and another inconclusive lab panel.
This guide breaks down what each test actually measures, when it is most useful, when it is misleading, and which one to request first if you are trying to understand where you are in transition.
What you’ll learn:
- What FSH, estradiol, and AMH each tell you physiologically
- Why a single FSH test often fails in early perimenopause
- The correct timing and cycle day for each measurement
- Which test to request first based on your age and symptoms
Quick answer
For most people aged 45 or older with typical perimenopause symptoms and cycle changes, the most useful “test” is still the clinical pattern, not a single FSH, estradiol, or AMH result. If testing is appropriate, paired FSH plus estradiol is mainly useful for early menopause or premature ovarian insufficiency questions, or for selected late-transition uncertainty; AMH can add ovarian-reserve context, especially around fertility planning, but it should not be used alone to diagnose perimenopause or menopause.
Key facts
- FSH is a pituitary signal that often rises as ovarian response declines, but it varies enough that one result cannot rule perimenopause in or out.
- Estradiol is ovarian output at one moment in time; in perimenopause it can be high, low, or normal within short windows.
- AMH is an ovarian-reserve marker and one of the stronger research predictors of proximity to the final menstrual period, but it does not give an exact menopause date.
- Guidelines generally diagnose perimenopause clinically in otherwise healthy people aged 45 or older, and reserve FSH testing for younger or uncertain cases.
- Hormonal contraception can suppress or obscure all three markers, so lab interpretation needs the method and timing context.
What each hormone measures
Quick definition: FSH (follicle-stimulating hormone) is the brain’s signal to the ovaries, estradiol is the main estrogen produced by ovarian follicles, and AMH (anti-Müllerian hormone) reflects the remaining ovarian reserve.
These three hormones describe different points on the reproductive axis:
- AMH = a proxy for ovarian reserve, not egg quality or a fertility guarantee
- FSH = how hard your brain is pushing the ovaries to respond
- Estradiol = what the ovaries are currently producing
Think of it as supply (AMH), demand (FSH), and output (estradiol). In young reproductive years, all three are balanced. In perimenopause, they decouple — and that decoupling is exactly what makes single-test interpretation so difficult.
For the symptom side of that decoupling, see estrogen vs progesterone in perimenopause, which compares estrogen volatility with progesterone-related cycle and sleep signals.
FSH in perimenopause
What it measures
Follicle-stimulating hormone is released from the pituitary gland. It rises as the ovaries become less responsive: the brain essentially turns up the volume when the ovaries stop answering normally. In suspected premature ovarian insufficiency or early menopause, elevated FSH on repeat samples can support the diagnosis. In otherwise healthy people aged 45 or older with typical symptoms, many guidelines identify perimenopause or menopause clinically rather than by FSH.
When FSH is useful
- Late perimenopause confirmation — when cycles are already skipping 60+ days
- Early menopause or premature ovarian insufficiency workup in people under 45, especially under 40
- Monitoring ovarian suppression during certain fertility or oncology treatments
Why FSH fails in early perimenopause
FSH is highly variable cycle to cycle during transition. In one month it may be 32 mIU/mL. Two months later, 8 mIU/mL. The ovaries intermittently respond; the brain intermittently pushes. A single reading catches one point on a swinging line.
The STRAW+10 staging criteria treat FSH as supportive rather than definitive during the transition because values can be highly variable. A single FSH and estradiol sample is not enough to definitively stage perimenopause.
The correct way to use FSH
- Draw on cycle day 2–4 if cycles are still present and early-follicular interpretation is the question
- Repeat when the result will change management; suspected premature ovarian insufficiency requires repeat elevated FSH rather than one draw
- Interpret alongside estradiol from the same draw; high FSH plus low estradiol is more informative than either marker alone
Typical values
| Stage | FSH (mIU/mL, day 2–4) |
|---|---|
| Reproductive years | 4–10 |
| Early perimenopause | 10–25, variable |
| Late perimenopause | 25–40, still fluctuating |
| Postmenopause | Often high, commonly 40+, but diagnosis is usually clinical when criteria are met |
Estradiol in perimenopause
What it measures
Estradiol (E2) is the dominant form of estrogen in reproductive years, produced mainly by developing ovarian follicles. It is the hormone responsible for endometrial growth, bone maintenance, cardiovascular regulation, cognitive effects, and most of the “feel” of a normal cycle.
When estradiol is useful
- Confirming a suspected high-estrogen phase (tender breasts, heavy bleeding, intense mood shifts)
- Evaluating hot flashes paired with low readings
- Monitoring HRT levels once therapy has started
- Fertility workup together with FSH, on cycle day 2–4
Why estradiol is deeply misleading alone
In perimenopause, estradiol does not decline smoothly — it swings wildly. A single reading may be:
- 250 pg/mL (high, above young adult average)
- 15 pg/mL (postmenopausal range)
- 80 pg/mL (textbook normal)
All within the same short window. Longitudinal SWAN data show that estradiol changes across the transition are non-linear and variable between individuals. One sample gives you one point on a moving curve.
The correct way to use estradiol
- Always paired with FSH from the same blood draw
- Interpret patterns over time via multiple samples, not a single value
- If tracking symptoms, correlate with cycle day rather than absolute number
Typical values (cycle day 2–4)
| Stage | Estradiol (pg/mL) |
|---|---|
| Reproductive years | 30–100 |
| Early perimenopause | Variable, 15–250+ |
| Late perimenopause | Variable, often <30 between cycles |
| Postmenopause | <20, stable |
AMH in perimenopause
What it measures
Anti-Müllerian hormone is produced by granulosa cells in small antral and pre-antral follicles. It reflects the remaining pool of eggs — the ovarian reserve. Unlike FSH and estradiol, AMH is not cycle-dependent. You can draw it on any day of the month.
When AMH is useful
- Estimating proximity to the final menstrual period in research and selected clinical contexts, especially when interpreted with age
- Fertility assessment, especially when considering IVF or egg freezing
- Adding ovarian-reserve context when other tests are ambiguous
- Baseline tracking in your late 30s and 40s if fertility planning, early menopause risk, or longitudinal context matters
The signal AMH gives that FSH and estradiol cannot
AMH can decline years before FSH rises. Cohort studies show that very low AMH can help estimate whether the final menstrual period is approaching, especially when combined with age. That lead time is useful context, but it is not a standalone diagnostic rule.
Limitations
- Does not predict the exact date of menopause
- Cannot replace clinical history or FSH where repeat FSH is specifically indicated
- Affected by hormonal birth control — can be artificially suppressed by 20–30%
- Not useful once already postmenopausal (values are uniformly undetectable)
Typical values
| Age range | AMH (ng/mL, typical) |
|---|---|
| 30–34 | 2.1–6.8 |
| 35–39 | 1.2–5.0 |
| 40–44 | 0.5–3.5 |
| 45–49 | 0.1–1.5 |
| 50+ | Often undetectable |
Side-by-side comparison
| Feature | FSH | Estradiol | AMH |
|---|---|---|---|
| What it reflects | Brain effort | Current output | Remaining reserve |
| Cycle dependent | Yes (day 2–4) | Yes (day 2–4) | No |
| Early perimenopause utility | Low | Low | Moderate, context-dependent |
| Late perimenopause utility | High | Moderate | Low |
| Menopause confirmation | Useful mainly in selected younger or uncertain cases | Supporting | Not used |
| Single-draw reliability | Poor | Very poor | Good |
| Affected by birth control | Suppressed | Suppressed | Suppressed ~20% |
| Predicts time to menopause | Weakly | Weakly | Stronger than FSH in cohorts, but not exact |
| Best use case | Clarify selected late or early-menopause questions | Pair with FSH or therapy monitoring | Ovarian-reserve and proximity context |
Which test should you request first?
If you are 38–44 with regular or mildly irregular cycles
Start with the clinical question. If you are asking about fertility timing, ovarian reserve, or unusually early transition, AMH may be the most useful first lab. If you are asking “am I in perimenopause?” and cycles are still regular, FSH and estradiol will often be normal or inconsistent, and symptoms plus cycle history may be more useful than a single panel. Retest AMH only if the result will change planning.
If you are 42–48 with clearly irregular cycles
Do not default to all three unless the result will change care. If you are under 45 or the diagnosis is uncertain, paired FSH plus estradiol on cycle day 2–4 can help. AMH adds reserve context, especially if fertility timing or early menopause risk is part of the question. The combination can suggest patterns:
- High FSH + low estradiol + low AMH → late perimenopause
- Normal FSH + wide estradiol + low AMH → mid-transition
- Normal FSH + normal estradiol + low AMH → early transition, symptoms likely starting
If you are 48+ with skipped periods over 60 days
Cycle history is usually more useful than a single lab. If you are 45 or older, not on hormonal contraception, and have gone 12 months without a period, menopause is usually identified clinically. If you are still skipping but not yet at 12 months, FSH may help only in selected uncertain cases. AMH adds little once transition is already obvious; estradiol can help when a clinician is evaluating therapy response or unusual symptoms.
If symptoms are severe but cycles look normal
AMH + thyroid (TSH, free T3, free T4) + metabolic panel. The priority is ruling out thyroid and catching metabolic shift before declaring perimenopause responsible.
The pairing that matters most
Regardless of which hormone test you request, it is often more actionable to pair the hormone context with cardiometabolic markers: fasting insulin, HbA1c, ApoB, hs-CRP, and vitamin D. These can shift during perimenopause and matter for your biological age trajectory during the perimenopausal transition. See our companion women over 40 health checklist for the full screening frame.
Interpretation pitfalls to avoid
“Normal FSH” does not mean “not perimenopausal”
A single FSH below 25 in a 45-year-old with irregular cycles and sleep disruption does not rule out perimenopause. It rules out menopause today. These are not the same.
Estradiol within range does not mean hormonally stable
An estradiol of 80 pg/mL on a single draw says very little about what it was last Tuesday or what it will be next month. Range is what matters, not a single value.
“Low AMH” is not “infertile”
Low AMH means smaller remaining pool, not that individual cycles cannot produce a healthy egg. For fertility decisions, AMH is one input among several.
Birth control confounds all three
Combined hormonal contraception and some high-dose progestogen methods can suppress or obscure FSH and estradiol, and hormonal contraception may lower AMH readings to varying degrees. Do not stop contraception just to “clean up” a lab result without a clinician plan and alternative contraception if pregnancy is possible.
Labs do not equal experience
Symptoms without lab confirmation are still real. Perimenopause can announce itself through sleep, mood, cognition, or cycle irregularity before any hormone crosses a threshold. Lab timing lags symptom timing by months to years.
How SuperAge tracks hormone trajectories
Hormone lab values alone are snapshots. Over time they form a trajectory — and it is the trajectory, not the snapshot, that matters for long-term health during transition. SuperAge is built around that principle.
Trend-first hormone tracking
Enter your FSH, estradiol, and AMH values as you get them, and SuperAge plots the slope rather than flagging single values. The slope is what tells you whether you are early, mid, or late perimenopause.
Hormones paired with biological age
The app links your hormone panel with the biomarkers that move during transition — fasting insulin, ApoB, hs-CRP — and shows how they are affecting your biological age together. For the full view of how these are weighted, see our how biological age is calculated explainer.
Cycle context when it still exists
If your Apple Watch is tracking cycles and sleep, SuperAge contextualizes lab timing automatically. A low estradiol drawn on day 20 means something very different than a low estradiol on day 3.
Symptom + data in one view
Hot flashes, sleep disruption, and energy logged in the app sit next to your biomarker trajectory. The pattern — not the isolated number — is what enables the right conversation with your clinician.
Frequently asked questions
Can one test tell me if I’m in perimenopause?
No single test is definitive in early or mid-perimenopause. For many people aged 45 or older, perimenopause is identified from symptoms and cycle change rather than hormone testing. If testing is appropriate because you are younger, uncertain, or evaluating fertility timing, AMH plus paired FSH and estradiol can add context, but staging is still about patterns across time.
Which hormone test declines first in perimenopause?
AMH usually declines earliest because it reflects ovarian reserve, which diminishes before FSH rises or estradiol becomes consistently low. This makes AMH useful for reserve and proximity context, but it loses value later when it approaches undetectable in most postmenopausal people.
Is estradiol useful at all if it swings so much?
Yes — for specific questions. Estradiol paired with FSH on the same draw helps distinguish late transition from earlier stages, and it informs HRT dosing if therapy is being considered. It is weak on its own but valuable in the right pairings.
Should I test hormones while on birth control?
Hormonal contraception can suppress or obscure FSH, estradiol, and AMH to varying degrees. If stopping contraception is not appropriate, interpret all three with that suppression context. If stopping is being considered for testing, do it only with clinician guidance and a contraception plan.
How often should I repeat these tests during perimenopause?
AMH once every 12–18 months in your 40s may be enough if fertility or reserve tracking will change decisions. FSH and estradiol are only informative when paired and interpreted with cycle day and age — repeat them when the result will change care, not just to chase fluctuations.
Key takeaways
- AMH, FSH, and estradiol measure different things — reserve, brain signal, and current output — and each peaks in usefulness at a different stage
- AMH is the strongest reserve/proximity marker among the three, but it is not a standalone diagnostic test for perimenopause or menopause
- FSH alone is unreliable in early-to-mid perimenopause because values swing widely from cycle to cycle
- Estradiol always requires pairing with FSH and ideally cycle day context; single values tell you very little
- Match the test to the question: AMH for reserve context, FSH for selected early-menopause or late-transition uncertainty, estradiol for paired interpretation and therapy context
Start tracking your transition clearly
Hormone testing during perimenopause only helps if you understand what each number can and cannot tell you, and if you track the trajectory rather than a single lab value.
Ready to see your hormone trajectory and biological age together? Download SuperAge and build the clearest picture of where you are in transition.
The information provided does not replace professional medical advice. Consult your healthcare provider before making decisions about hormone testing, interpretation, or any form of hormone therapy.
References
- NICE. (2024). Menopause: identification and management. https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
- ACOG. (2025). Do I need to have testing of my hormone levels during perimenopause? https://www.acog.org/womens-health/experts-and-stories/ask-acog/do-i-need-to-have-testing-of-my-hormone-levels-during-perimenopause
- Harlow SD, et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10 (STRAW+10). https://pubmed.ncbi.nlm.nih.gov/22344196/
- Freeman EW, et al. (2012). Anti-Müllerian hormone as a predictor of time to menopause in late reproductive age women. https://pubmed.ncbi.nlm.nih.gov/22378815/
- Randolph JF, et al. (2011). Change in follicle-stimulating hormone and estradiol across the menopausal transition. https://pubmed.ncbi.nlm.nih.gov/21159842/
- Finkelstein JS, et al. (2020). Antimüllerian hormone and impending menopause. https://pubmed.ncbi.nlm.nih.gov/31965189/
- Gizzo S, et al. (2019). Assessment of circulating anti-Müllerian hormone in women using hormonal contraception: a systematic review. https://pubmed.ncbi.nlm.nih.gov/31314652/
Last updated: 2026-06-08. This article is regularly reviewed to ensure accuracy.
Related Articles
Estrogen vs progesterone in perimenopause: which affects aging more?
Estrogen vs progesterone in perimenopause: compare sleep, cycles, metabolism, labs, and biological-age signals without overreading one hormone.
